The CD4+ Treg cell population in the TME is the main cell group leading to the inactivation of effector T cells and is also one of the factors that promote tumor progression and metastasis. Therefore, targeting CD4+ Treg cells directly is a promising strategy to effectively prevent tumor metastasis and progression. IT1208, a defucosylated humanized anti‐CD4 monoclonal antibody, demonstrated tolerable toxicities and encouraging preliminary efficacy in a Phase I clinical trial involving 11 patients with advanced solid tumors.368. This evidence concerns the gene CD4 and neoplasm.